HC Wainwright & Co. Reiterates Buy on Axsome Therapeutics, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Axsome Therapeutics (NASDAQ:AXSM) and maintained a price target of $190.
June 06, 2024 | 10:16 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Axsome Therapeutics and maintained a price target of $190.
The reiteration of a Buy rating and a high price target of $190 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive short-term price appreciation for Axsome Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100